Synopsis of new antiangiogenetic factors, mutation compensation agents, and monoclonal antibodies in target therapies of breast cancer

Journal of B.U.ON.

Volumn 15, Issue 4, 2010, Pages 639-646

  Grammatikakis, I ^a   Zervoudis, Stefanos ^b   Kassanos, D ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b Lito Maternity Hospital   (Greece)

Author keywords

Antiangiogenetic therapies; Breast cancer; Gene therapy; Mutation compensation

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MACROPHAGE ELASTASE; METHOTREXATE; PENTRAXIN 3; PLASMA PROTEIN; PLASMINOGEN KRINGLE 5; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANTIANGIOGENIC GENE THERAPY; ANTISENSE THERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER MORTALITY; CARCINOGENESIS; DRUG MECHANISM; DRUG TARGETING; GENE INSERTION; GENE MUTATION; GENOMIC INSTABILITY; HEART ARRHYTHMIA; HUMAN; MOLECULAR THERAPY; REVIEW; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MUTATION;

EID: 78651380327     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Isborne RJ, Hamshere MG. A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. Cancer Res 2000; 60: 3706-3712.
2. Johannsdottir HK, Johannsdottir G, Agnarsson BA et al. Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables. Anticancer Res 2004; 24: 2681-2687.
3. Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 2004; 9: 361-377. (Pubitemid 39014548)
4. De Jong NM, Nolte IM, te Meerman GJ et al. Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility. J Med Genet 2002; 39: 225-242.
5. Takahashi T, Nau MM, Chiba I et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491-494.
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991; 253: 49-53.
7. Bland KI. The 1999 James Ewing Lecture: in pursuit of oncogenesis and neoplastic therapy. Ann Surg Oncol 1999; 6: 528-541.
8. Nass SJ, Dickson RB. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 1997; 44: 1-22.
9. Saldanha G, Ghura V, Potter L, Fletcher A. Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation. Br J Dermatol 2004; 151: 157-164.
10. Brown JM, Giaccia AJ. The Unique Physiology of Solid Tumors: Opportunities (and Problems) for Cancer Therapy. Cancer Res 1998; 58: 1408-1416.
11. Benjamin LE, Bergers G. Angiogenesis: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410.
12. Rafii S, Heissig B, Hattori K et al. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther 2002; 9, 631-641.
13. McCormick F. Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001; 1: 130-141.
14. Chen QR, Mixson AJ. Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications. Front Biosci 1998; 3: 997-1004.
15. McKenzie T, Liu Y, Fanale M, Swisher SG, Chada S, Hunt KK. Combination therapy of Ad-mda7 and trastuzumab increases cell death in Her-2/neu overexpressing breast cancer cells. Surgery 2004; 136: 437-442.
16. Holt JT, Thompson ME, Szabo C et al. Growth retardation and tumor inhibition by BRCA1. Nat Genet 1996; 12: 298-302. (Pubitemid 26080089)
17. Holt JT. Breast cancer genes: therapeutic strategies. Ann NY Acad Sci 1997; 833: 34-41. (Pubitemid 28045237)
18. Jiang Z, Zacksenhaus E. Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precautious differentiation, and adenocarcinoma. J Cell Biol 2002; 156: 185-198.
19. Craig C, Wersto R, Kim M et al. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclinCdk activity in human breast cancer cells. Oncogene 1997; 14: 2283-2289.
20. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002; 1: 347-355.
21. Roychowdhury D, Lahn M. Antisense therapy directed to protein kinase C-alpha: a potential role in breast cancer. Semin Oncol 2003; 30: 30-33.
22. Nahta R, Esteva FJ. BCL-2 antisense oligonucleotides: a potential novel strategy for the treatment of breast cancer. Semin Oncol 2003; 30: 143-149.
23. Salatino M, Schillaci R, Proietti CJ et al. Inhibition on in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 2004; 23: 5161-5174.
24. Lee WJ, Robinson JA, Holman NA, McCall MN, Roberts-Thompson SJ, Monteith GR. Antisense mediated inhibition of plasma membrane calcium ATPase suppresses proliferation of MCF-7 cells. J Biol Chem 2005; 280: 27076-27084.
25. Wang YH, Liu S, Zhang G et al. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 2005; 7: 220-228.
26. Iyo M, Kawasaki H, Taira K. Construction of an allosteric transmaxizyme targeting for two distinct oncogenes. Nucleic Acids Res 2002; 2 (Suppl): 115-116.
27. Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles and state of the art in suicide gene therapy. Mol Biotechnol 2005; 30: 71-88.
28. Stribbling SM, Friedlos F, Martin J, et al. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum Gene Ther 2000; 11: 285-292.
29. O'Malley BW, Cope KA, Chen SH, Li D, Schwarta MR, Woo SL. Combination gene therapy for oral cancer in a murine model. Cancer Res 1996; 56: 1737-1741.
30. Braybrooke JP, Slade A, Deplaque G et al. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res 2005; 11: 1512-1520.
31. Stoff-Khalili MA, Dall P, Curiel DT. Gene therapy for carcinoma of the breast. Cancer Gene Ther 2006; 13: 633-647.
32. Grim JE, Siegal GP, Alvarez RD, Curiel DT. Intracellular expression of the anti-erbB-2 sFn N29 fails to accomplish efficient target modulation. Biochem Biophys Res Commun 1998; 250: 699-703.
33. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
34. Moser TL, Kenan DJ, Ashley TA et al. Endothelial cell surface F1-FO ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci USA 2001; 98: 6656-6661.
35. Moser TL, Stack MS, Asplin I et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999; 96: 2811-2816.
36. Yamaguchi A, Urano T, Fushida S et al. Inverse association of nm23-H1 expression by colorectal cancer with liver metastasis. Ann Surg 1993: 1020-1025.
37. Miyazaki H, Fukuda M, Ishijima Y et al. Overexpression of nm23-H2/NDP kinase B in a human oral squamous cell carcinoma cell line results in reduced metastasis, differentiated phenotype in the metastatic site, and growth factor independent proliferative activity in culture. Clin Cancer Res 1999; 5: 4301-4307.
38. Steeg PS, Cohn KH, Leone A. Tumor metastasis and nm23: current concepts. Cancer Cells 1991; 3: 257-262.
39. Ismail NI, Kaur G, Hashim H, Hassan MS. Nuclear localization and intensity of staining of nm23 protein is useful marker for breast cancer progression. Cancer Cell Int 2008; 8: 6.
40. Tschiedel S, Gentilini C, Lange T et al. Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia. Leukemia 2008; 22: 1542-1550.
41. Rumjahn SM, Javed MA, Wong N, Law WE, Buxton IL. Purinergic regulation of angiogenesis by human breast carcinoma-secreted nucleoside diphosphate kinase. Br J Cancer 2007; 97: 1372-1380.
42. Iain L, Buxton O. Inhibition of Nm23H2 Gene Product (NDPK-B) by angiostatin, polyphenols and nucleoside analogs. Proc West Pharmacol Soc 2008; 51: 30-34.
43. Agarwal A, Munoz-Nájar U, Klueh U, Shih S-C, Claffey KP. N-Acetyl-Cysteine Promotes Angiostatin Production and Vascular Collapse in an Orthotopic Model of Breast Cancer. Am J Pathol 2004; 164: 1683-1696.
44. O'Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
45. Perri SR, Martineau D, Francois M et al. Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways. Mol Cancer Ther 2007; 6: 441-449.
46. LeRoy EC. Systemic sclerosis: a vascular perspective. Rheum Dis Clin North Am 1996; 22: 675-694.
47. D'Alessio S, Fibbi G, Cinelli M et al. Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. Arthritis Rheum 2004; 50: 3275-3285.
48. Margheri F, Manetti M, Serrati S et al. Domain 1 of the urokinase type plasminogen activator receptor is required for its morphologic and functional β2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum 2006; 54: 3926-3938.
49. Giusti B, Fibbi G, Margheri F et al. Amodel of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006; 8: R115.
50. Margheri F, Serrati S, Lapucci A et al. Systemic Sclerosis-Endothelial Cell Antiangiogenic Pentraxin 3 and Matrix Metalloprotease 12 Control Human Breast Cancer Tumor Vascularization and Development in Mice. Neoplasia 2009; 11: 1106-1115.
51. Ménard S, Fortis S, Castiglioni F et al. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61(Suppl 2): 67-72.
52. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
53. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
54. Slamon DJ, Leyland-Jones B, Shak S et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer: a phase III, multinational, randomized controlled trial. N Engl J Med 2001; 344: 783-792.
55. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
56. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188.
57. Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89: 139-147.
58. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
59. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
60. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
61. Metcalfe S, Evans J, Priest G. HARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer N Z Med J 2007; 120: 1U2593.
62. Sedge GW Jr. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002; 29 (Suppl 11): 104-110.
63. Linderholm B, Lindh B, Beckman L et al. The prognostic value of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) and associations to first metastasis site in 1307 patients with primary breast cancer. Proc Am Soc Clin Oncol 2001; 20: 4a (abstr).
64. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61: 5407-5414.
65. Chan A, Miles DW, Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer Ann Oncol 2010 Mar 24 (in press).